Last reviewed · How we verify
Irbesartan (Aprovel)
Irbesartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release to lower blood pressure.
Irbesartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release to lower blood pressure. Used for Hypertension, Diabetic nephropathy in patients with type 2 diabetes and hypertension.
At a glance
| Generic name | Irbesartan (Aprovel) |
|---|---|
| Sponsor | Sanofi |
| Drug class | Angiotensin II receptor blocker (ARB) |
| Target | AT1 receptor (Angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
As an angiotensin II receptor blocker (ARB), irbesartan selectively antagonizes AT1 receptors on vascular smooth muscle and adrenal tissue. This prevents angiotensin II-mediated vasoconstriction and sodium retention, leading to vasodilation and reduced blood volume, thereby decreasing systemic blood pressure. It is commonly used in hypertension and diabetic nephropathy where it provides both blood pressure reduction and renal protective effects.
Approved indications
- Hypertension
- Diabetic nephropathy in patients with type 2 diabetes and hypertension
Common side effects
- Dizziness
- Fatigue
- Musculoskeletal pain
- Hyperkalemia
- Cough
Key clinical trials
- Bariatric Surgery and Pharmacokinetics of Irbesartan
- Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension (PHASE4)
- Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN) (PHASE3)
- Irbesartan and Atenolol in Hypertensive Heart Disease (PHASE2, PHASE3)
- Angiotensin II Antagonist in Severe Sepsis (PHASE3)
- Saving Residual Renal Function Among Haemodialysis Patients Receiving Irbesartan (PHASE3)
- I SELECT - Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy (PHASE4)
- I PREVENT - Irbesartan In Hypertensive Diabetic Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Irbesartan (Aprovel) CI brief — competitive landscape report
- Irbesartan (Aprovel) updates RSS · CI watch RSS
- Sanofi portfolio CI